about
Immunological Landscape and Clinical Management of Rectal CancerMyeloid-derived cells are key targets of tumor immunotherapyCorrelation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse model.Overexpression of apolipoprotein A-I fused to an anti-transforming growth factor beta peptide modulates the tumorigenicity and immunogenicity of mouse colon cancer cells.Commentary on Pharmacometrics for Immunotherapy.Targeting NK-cell checkpoints for cancer immunotherapy.Cellular immunotherapies for cancer.CORRIGENDUM: Commentary on Pharmacometrics for ImmunotherapyAn inducible promoter responsive to different porphyrinogenic stimuli improves gene therapy vectors for acute intermittent porphyria.Treatment of Chronic Viral Hepatitis in Woodchucks by Prolonged Intrahepatic Expression of Interleukin-12.Engineered fibroblast growth factor 19 protects from acetaminophen-induced liver injury and stimulates aged liver regeneration in mice.Enhancement of antibody-dependent cellular cytotoxicity of cetuximab by a chimeric protein encompassing interleukin-15.Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatosis: development of an FGF19-based chimeric molecule to promote fatty liver regeneration.Intravenous immunoglobulin promotes antitumor responses by modulating macrophage polarization.Systemic messenger RNA as an etiological treatment for acute intermittent porphyriaTGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal AntibodiesRevisiting Interleukin-12 as a Cancer Immunotherapy AgentEpistatic Oncogenic Interactions Determine Cancer Susceptibility to ImmunotherapyCellular cytotoxicity is a form of immunogenic cell deathInternational Symposium: Trailblazing in Cancer Immunotherapy, October 29-31, 2017, Pamplona, SpainNeoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastomaImmune Desertic Landscapes in Hepatocellular Carcinoma Shaped by β-Catenin ActivationDaratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cellsTreatment of Experimental Autoimmune Encephalomyelitis by Sustained Delivery of Low-Dose IFN-α
P50
Q26768531-D97A2F33-D627-4524-B34E-CE383477A63FQ28388246-71C9588A-F5D8-49D3-8D0D-4D0E96A719BEQ37718304-B0B5434F-13B0-46A0-99FD-DC74D5869F03Q38896948-C8C1CB9A-EF20-4CE3-BC28-CCE3BB8748AFQ39082975-97776745-625B-43F9-99DD-589B3E01EAF9Q39150423-F5264D3E-24FE-4E72-AE02-3FCB7A0A9E5BQ39389608-F94F2B7D-7FE0-4240-92DB-E77266DC9543Q42291003-E9101EC2-545E-4CB4-9EBF-195B838C7D71Q45872939-09038F2D-4DCC-410B-8FAF-7E626669D08AQ46001418-46C904D4-3414-489B-9472-C8C5973435A4Q46640064-CDE859AF-6CB2-4C99-9549-D431F1B3C34CQ47225780-1F948FA8-99B6-4B98-BDB4-2D6E6C99C739Q50934377-EDAE185A-E9F5-4AA4-887F-75656E00ED1AQ51041640-B20D2983-FF40-43FF-861C-22748D98AE02Q57295544-4BAA96EB-C3C0-4426-A567-6D8DAD0C4AB4Q63865741-EA702842-B9A4-4475-AADA-EEE8447A23E0Q88084895-B50559B4-421C-45D1-A405-F16DAC672194Q89392336-38A41D42-1D23-4F28-B34B-12EDBA202E0BQ90690167-22CF58C3-0A74-45C7-9BB4-52DAA2C5572EQ91291801-BD5D5919-1FA0-4452-9AC1-25F36A7F8D36Q91451450-274B5098-05D3-4A6E-8476-836DBC92120DQ92350709-F078C276-7A72-4FD2-AEDE-FAD0B360AA76Q92385628-B00E20F9-021C-44EE-956A-8168D72658DFQ92824612-0F952CCD-4E6B-4280-B3E2-EA04404D037E
P50
description
researcher
@en
name
Pedro Berraondo
@en
type
label
Pedro Berraondo
@en
prefLabel
Pedro Berraondo
@en
P31
P496
0000-0001-7410-1865